Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Intranasales Oxytocin für Methamphetamin-Entzug bei Frauen (mOXY)

1. Oktober 2026 aktualisiert von: Turning Point

Eine Open-Label-Pilotstudie mit intranasalem Oxytocin für den Methamphetamin-Entzug bei Frauen

Methamphetamine use disorder (MUD) is a significant public health concern with burden to individuals, families and health systems estimated to cost over $5 billion annually in Australia. In 2016/17 there were 49,670 Australian treatment episodes for MUD, the first step of which typically involves inpatient withdrawal. Currently there are no approved medications to help manage methamphetamine withdrawal and consequently many people drop out of treatment prematurely, leaving them vulnerable to relapse.

Oxytocin is a candidate medication that has the potential to increase treatment retention, reduce withdrawal syndrome severity, increase post-withdrawal treatment engagement and reduce relapse rates.

The aim of this pilot study is to investigate whether intranasal oxytocin can improve withdrawal treatment outcomes in adult women with MUD. The study will examine the feasibility of intranasal oxytocin as a treatment for methamphetamine withdrawal in women. This will be explored by assessing length of stay in residential withdrawal, withdrawal symptom severity, post-discharge treatment engagement and relapse rates in a group of women who are prescribed intranasal oxytocin during their medically supervised methamphetamine withdrawal at a residential detoxification program. The safety of intranasal oxytocin will also be assessed. A secondary objective of the study is to conduct an exploratory analysis regarding participants' capacity to interact effectively with others, as well as changes in social networks and/or engagement with therapeutic services.

There is an observational sub-study affiliated with this main pilot study that is optional for individuals recruited to the main pilot trial to additionally participate in. This sub-study aims to investigate how sleep quality and patterns change before, during, and after detoxification from methamphetamine in women. MUD and sleep disturbances have a complex bidirectional relationship. The use of methamphetamine is known to disrupt sleep quality and the circadian rhythm, although withdrawal from methamphetamine also induces significant sleep-wake cycle changes. There is evidence that methamphetamine disrupts functions regulated by the circadian rhythm. Furthermore, disruptions in circadian rhythms, including mutations in key genes, increases the propensity for addiction. Evaluation of how chronic methamphetamine use may disrupt rhythmicity, and vice versa, may provide invaluable information with regard to potential treatment options of methamphetamine use disorder. There has been little focus, so far, on the therapeutic potential of circadian rhythm modifiers as treatment options in the addiction space, as sleep disturbances have often been merely viewed as a consequence of substance use.

Specific to the sub-study, participants will be asked to wear an actigraphy watch. The actigraphy watch device will be worn for at least 7 days prior to, 7 days during, and 7 days post methamphetamine detoxification. This is the only difference between the sub-study and the main pilot study; there are no other additional requirements or assessments involved in the actigraphy sub-study.

Studienübersicht

Status

Abgeschlossen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

10

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Victoria
      • Richmond, Victoria, Australien, 3121
        • Turning Point

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Adult females (sex assigned at birth) aged ≥18 to ≤65 years, admitted to the Turning Point Addiction Medicine Unit.
  • Meeting DSM-5 criteria for Methamphetamine Use Disorder, moderate or severe (assessed by treating physician on pre-admission to residential withdrawal).
  • Able to comply with study protocols.
  • Able to provide informed consent to participate.

Exclusion Criteria:

  • Non-English-speaking women.
  • Women lactating, pregnant or of childbearing potential who are not willing to use an effective means of contraception for the duration of the trial.
  • Meeting DSM-5 criteria for moderate-severe substance use disorder other than methamphetamine, nicotine and cannabis, as assessed by treating physician on pre-admission to residential withdrawal.
  • Clinically significant or unmanaged medical or psychiatric illness (e.g., renal insufficiency, cirrhosis, unstable hypertension, unstable diabetes mellitus, seizure disorder, history of DSM-5 psychotic or bipolar disorder, current severe major depression, current suicidal ideation), assessed by treating physician on pre-admission to residential withdrawal.
  • Current participation in another trial.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intranasal oxytocin

Participants will receive oxytocin by intranasal spray under clinician supervision (1 insufflation equating to an active dose of 24 IU) twice daily (i.e., 48 IU per day), delivered over 7 days of a residential inpatient withdrawal admission.

Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Feasibility assessment
Zeitfenster: Screening to Admission Day 1

Feasibility, operationalised as the proportion of all screened participants who were ineligible before enrolment, with ≤20% indicating feasibility.

Screening to Admission Day 1

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Length of stay in the inpatient withdrawal unit
Zeitfenster: Admission Day 1 to Admission Day 7

Medical chart review to determine number of days stayed in the inpatient withdrawal unit.

Admission Day 1 to Admission Day 7
Methamphetamine withdrawal symptom severity
Zeitfenster: Admission Day 1 to Admission Day 7

Individual average score across the participants' length of stay in the inpatient withdrawal unit on the Amphetamine Withdrawal Questionnaire (scores on this measure range from 0 to 40 with higher score indicating greater severity).

Admission Day 1 to Admission Day 7
Methamphetamine craving
Zeitfenster: Admission Day 1 to Admission Day 7

Individual average score across the participants' length of stay in the inpatient withdrawal unit on the Visual Analogue Scale for Craving (scores on this measure range from 0 to 100, with higher scores indicating greater craving).

Admission Day 1 to Admission Day 7
Sleep dysfunction
Zeitfenster: Admission Day 1 to Admission Day 7

Individual average score across the participants' length of stay in the inpatient withdrawal unit on the Insomnia Severity Index (scores on this measure range from 0 to 28, with higher scores indicating greater sleep dysfunction).

Admission Day 1 to Admission Day 7
Mood disturbance
Zeitfenster: Admission Day 1 to Admission Day 7

Individual average score across the participants' length of stay in the inpatient withdrawal unit on the Abbreviated Profile of Mood States - Revised Version (total mood disturbance scores on this measure range from 0 to 116, with higher scores indicating greater disturbance)

Admission Day 1 to Admission Day 7
Methamphetamine relapse
Zeitfenster: 1-month post-discharge

Relapse is defined as a yes/no result for any methamphetamine use in the month following discharge from the withdrawal unit, as assessed using the Timeline Follow Back measure.

1-month post-discharge
Treatment engagement
Zeitfenster: 1-month post-discharge

Yes/No attendance at any form of treatment to assess treatment engagement at 1-month post-discharge.

1-month post-discharge
Therapeutic alliance
Zeitfenster: 1-month post-discharge

Working Alliance Inventory-Short Form Revised will be used to assess therapeutic alliance with nominated primary provider (scores on this measure range from 12 to 60, with higher scores indicating better therapeutic alliance).

1-month post-discharge
Incidence of adverse events
Zeitfenster: Day 1 of admission to 1-month post-discharge

Number and categorisation of reported adverse events.

Day 1 of admission to 1-month post-discharge
Perceived burden of intranasal oxytocin
Zeitfenster: Admission Day 1 to Admission Day 7

Individual average score across the participants' length of stay in the inpatient withdrawal unit on the Visual Analogue Scale for Medication Utilisation Burden (scores on this measure range from 0 to 100, with higher scores indicating greater perceived burden).

Admission Day 1 to Admission Day 7
Perceived satisfaction with intranasal oxytocin
Zeitfenster: Admission Day 3 and 7

Satisfaction with medication based on results from the Treatment Satisfaction Questionnaire (scores on this measure range from 0 to 100, with higher scores indicating greater satisfaction).

Admission Day 3 and 7
Severity of Clinical Condition
Zeitfenster: Baseline to 1-month post-discharge

Change in clinician-rated assessment of the participant's condition using the Clinical Global Impression - Severity Scale (scores on this measure range from 1 to 7, with higher scores indicating poorer condition).

Baseline to 1-month post-discharge
Improvement of Clinical Condition
Zeitfenster: 1-month post-discharge

Clinician-rated assessment of the participant's overall clinical condition, substance use, and related problems compared to a baseline assessment, using the Clinical Global Impression - Improvement Scale (scores on this measure range from 5 to 35, with higher scores indicating a worsening of condition in comparison to baseline).

1-month post-discharge

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in facial emotion recognition
Zeitfenster: Baseline to 1-month post-discharge

Change in total score on the Facial Emotion Recognition Task at 1-month post-discharge compared to baseline.

Baseline to 1-month post-discharge
Change in mentalisation
Zeitfenster: Baseline to 1-month post-discharge

Change in total score on the Reading the Eyes in the Mind Task at 1-month post-discharge compared to baseline.

Baseline to 1-month post-discharge
Change in social functioning
Zeitfenster: Baseline to 1-month post-discharge

Change in score on the Social Functioning Scale at 1-month post-discharge compared to baseline (scores on this measure range from 0 to 24, with higher scores indicating poorer social functioning).

Baseline to 1-month post-discharge
Sleep-wake cycles [part of the optional sub-study]
Zeitfenster: 7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.

Change in sleep-wake cycles, as assessed via actigraphy monitoring, before, during and after methamphetamine detoxification.

7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.
Objective assessment of sleep quality [part of the optional sub-study]
Zeitfenster: 7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.

Change in sleep quality, as assessed via actigraphy monitoring, before, during and after methamphetamine detoxification.

7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.
Objective assessment of sleep duration [part of the optional sub-study]
Zeitfenster: 7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.

Change in sleep duration, as assessed via actigraphy monitoring, before, during and after methamphetamine detoxification.

7 days prior to, 7 days during, and 7 days post methamphetamine detoxification.
Subjective sleep quality
Zeitfenster: Baseline to 1-month post-discharge.

Change in score on the Pittsburgh Sleep Quality Index at 1-month post-discharge compared to baseline (scores on this measure range from 0 to 21, with higher scores indicating poorer sleep quality).

Baseline to 1-month post-discharge.
Rhythmicity of sleep-wake cycles
Zeitfenster: Baseline to 1-month post-discharge.

Sleep rhythmicity and categorisation of morning-evening preference grouping using the Morningness-Eveningness Questionnaire-Reduced Scale (scores on this measure range from 4-25, where higher scores are indicative of morning-type preferences - scores are categorised into one of 5 preference groups, ranging from "Definitely Evening Type" to "Definitely Morning Type").

Baseline to 1-month post-discharge.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Shalini Arunogiri, Turning Point, Eastern Health, Monash University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. März 2023

Primärer Abschluss (Tatsächlich)

28. März 2024

Studienabschluss (Tatsächlich)

28. März 2024

Studienanmeldedaten

Zuerst eingereicht

14. Februar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. März 2023

Zuerst gepostet (Tatsächlich)

8. März 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • E21-014-75603
  • NCR3SF18 (Andere Zuschuss-/Finanzierungsnummer: NCCRED)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren